Best Neurologists for Myasthenia Gravis Treatment in India

Myasthenia gravis is a chronic autoimmune neuromuscular disease in which antibodies impair or destroy receptors at the junction between nerves and voluntary muscles, producing characteristic weakness that typically worsens with activity and improves with rest.

Common presentations include drooping of one or both eyelids (ptosis), double vision, difficulty swallowing or speaking, facial muscle weakness, and fatigue or weakness in the arms and legs that fluctuates throughout the day and worsens with sustained effort. In some individuals, weakness of the breathing muscles can develop, representing a medical emergency. Experiencing any combination of these symptoms does not confirm a diagnosis of myasthenia gravis, as several other neurological and muscular conditions can produce similar features.

Diagnosis typically involves a detailed clinical history and neurological examination, followed by blood tests to detect acetylcholine receptor (AChR) antibodies or, in seronegative cases, muscle-specific kinase (MuSK) or LRP4 antibodies. Electrophysiological studies — specifically repetitive nerve stimulation and single-fibre electromyography (SFEMG), the most sensitive electrodiagnostic test available — are used to confirm impaired neuromuscular transmission. Imaging of the chest (CT or MRI) is routinely performed to screen for thymoma or thymic hyperplasia, and disease severity is often classified using the Myasthenia Gravis Foundation of America (MGFA) clinical classification, which ranges from Class I (ocular involvement only) through Class V (intubation required), helping to guide treatment intensity.

Treatment is highly individualised based on MGFA class, antibody profile, age, the presence of thymoma, and overall health, and ranges from medication alone in mild cases to surgical and advanced immunological interventions in more severe or refractory disease. Symptom control is typically initiated with acetylcholinesterase inhibitors, while long-term immune modulation is pursued with corticosteroids and steroid-sparing immunosuppressants; for eligible patients — particularly those under 60 or those found to have thymoma — thymectomy (surgical removal of the thymus) has been shown to improve long-term outcomes. In myasthenic crisis or rapidly worsening disease, short-term rescue therapies such as plasmapheresis (plasma exchange) or intravenous immunoglobulin (IVIg) are used to stabilise the patient quickly.

The majority of patients with myasthenia gravis are managed primarily through non-surgical means, including acetylcholinesterase inhibitors (such as pyridostigmine) for symptomatic relief, corticosteroids, and long-term immunosuppressant medications such as azathioprine, mycophenolate mofetil, or tacrolimus. Newer targeted biological therapies — including complement inhibitors (eculizumab, ravulizumab) and neonatal Fc receptor (FcRn) antagonists (efgartigimod, rozanolixizumab) — have expanded non-surgical options for refractory cases. Monitoring, dose adjustments, and avoidance of medications known to exacerbate MG are ongoing components of non-surgical care; the appropriateness of any specific agent or regimen depends entirely on individual assessment by a treating clinician.

Myasthenia Gravis Treatment may be considered only when it is appropriate for the confirmed diagnosis and the expected benefit outweighs the individual risks. The decision may depend on symptom severity, investigation results, previous treatment, overall health and the patient's goals. A specialist should discuss alternatives and recovery before any procedure is planned.

Myasthenia gravis is primarily evaluated and managed by a neurologist, specifically one with expertise in neuromuscular disorders; where thymoma is identified or thymectomy is being considered, a thoracic surgeon experienced in thymic surgery becomes an essential part of the care team. In complex or refractory cases, input from a clinical immunologist or a specialist in neuro-ophthalmology (for isolated ocular MG) may also be sought.

When selecting a specialist or facility, it is worth asking about their experience managing MG across the full MGFA severity spectrum, whether the centre offers multidisciplinary input including thoracic surgery, respiratory medicine, and immunology, and what follow-up and crisis management protocols are in place — given that myasthenic crisis can require urgent, coordinated care.

Share a concise medical summary, symptom timeline, previous diagnoses, investigation and imaging reports, procedure or biopsy reports where relevant, current medicines, allergies and related treatment records. Provide clear copies with translations when needed. The reviewing doctor may request additional information before giving an opinion.

Our care coordination team can review the initial information, help identify suitable doctors and hospitals, request a medical opinion where available, explain next steps and indicative cost information, and support practical planning before travel. A remote opinion does not replace an in-person examination or emergency care.